J

Johnson & Johnson

Makes prescription drugs and medical devices

Neuroscience Sales Specialist

Full-TimeDeadline 10/23/26
$79k - $178.3k+ Long-term incentive program
Mid
Bachelor's, Master's, MBA, PhD
Boston, MA, USA
In PersonMust live in or be willing to relocate to the Boston-area geography; travel up to 50%, including possible overnight and weekend travel.
Sales & Account ManagementField Sales

About the job

Requirements
  • A minimum of a bachelor's degree is required.
  • A valid driver's license issued in one of the fifty United States is required.
  • A minimum of three years of relevant work experience in healthcare sales, account management, customer-facing roles, business-to-business sales, or recent transition from active-duty military is required.
  • The candidate must be able to travel up to 50%, which may include overnight and weekend travel.
  • The candidate must live in the geography or be willing to relocate to it.
  • Experience using a structured sales approach, adapting engagement based on customer needs, and confirming clear next steps to advance appropriate adoption is required.
  • Experience identifying account obstacles, gathering key information, determining next steps, and escalating appropriately when needed is required.
  • Experience building trust-based relationships with customers and internal partners through clear communication, follow-through, and collaboration is required.
  • Experience creating and executing a territory or account plan by setting priorities, aligning activities to goals, and adjusting based on insights and results is required.
  • Experience partnering across internal teams by engaging the right stakeholders, sharing relevant information, and coordinating actions that improve the customer experience is required.
  • Ability to identify key information and relationships between pieces of information, and use business data presented in graphs, tables, and reports to extract insights and develop data-driven solutions using appropriate analysis is required.
Responsibilities
  • Engage healthcare professionals and stakeholders using customer-specific approaches aligned to practitioner priorities, institutional needs, and patient outcomes.
  • Develop expertise in the neuroscience portfolio, including Caplyta, and apply approved clinical and business knowledge to support customer engagement, territory priorities, and patient-focused outcomes.
  • Communicate approved clinical and scientific information using authorized materials and follow information-sharing policies.
  • Develop and execute strategic pre-call and account plans focused on actions that drive business outcomes aligned to territory, district, regional, and national goals, and review progress regularly.
  • Identify, prioritize, and engage key stakeholders who influence business, tailoring messages and resources to each stakeholder's role.
  • Optimize selling time and stakeholder access across accounts and care settings.
  • Analyze business and market data to identify opportunities, assess performance, and adjust execution strategies.
  • Apply knowledge of payer access, affordability, and reimbursement dynamics to support appropriate utilization.
  • Build trust-based relationships with customers and internal partners through clear communication, follow-through, and collaboration.
  • Conduct two-way clinical and scientific discussions that address customer needs, support informed decision-making, and build long-term trust.
  • Collaborate with internal partners to support coordinated customer engagement across face-to-face, virtual, and digital channels as available.
  • Collaborate with customers and internal partners to support patient-centered care, coordinated treatment planning, and appropriate therapy utilization and adherence.
  • Partner across functions to create shared accountability, deliver a consistent customer experience, and achieve business objectives.
  • Share field insights and observations to inform planning, prioritization, and continuous improvement.
  • Adhere to all healthcare compliance policies and guidelines.
  • Use customer relationship management systems and approved artificial-intelligence-enabled tools where available to strengthen prioritization, planning, and follow-through while maintaining privacy, data integrity, and policy alignment.
Desired Qualifications
  • A master's degree, Master of Business Administration, or PhD is preferred.
  • Experience in the neuroscience therapeutic area is preferred.
  • Experience working in complex accounts, institutional environments, or integrated delivery networks is preferred.
  • Experience navigating payer access, reimbursement, affordability, or other dynamics that affect appropriate utilization is preferred.
  • A demonstrated track record of consistently achieving sales goals in a competitive selling environment is preferred.
  • Demonstrated ability to influence internal and external stakeholders to support coordinated customer engagement is preferred.
  • Demonstrated commitment to learning emerging technologies such as artificial intelligence through exploration, iteration, and applying new tools over time is preferred.
  • Experience communicating clinical and scientific information using approved materials, accurately explaining evidence, and tailoring messaging to customer priorities within guidelines is preferred.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.

CNBC
Oct 13th, 2026
J&J beats estimates and lifts forecast to $101.2B, but Middle East conflict hurts device sales

Johnson & Johnson (J&J) beat earnings estimates, but the Middle East conflict hurt its medical-device sales in the region. Chief financial officer Joe Wolk said Gulf states such as Kuwait, the UAE, and Saudi Arabia are shifting budgets towards defence. The conflict has not yet raised J&J's costs. Tremfya sales rose 68% to $2.4 billion, beating estimates of about $2.19 billion. Stelara sales, which face generic competition, fell 54% to $716 million, above expectations of $591 million. Darzalex sales rose about 16% to $4.24 billion, short of the $4.4 billion expected. J&J raised its full-year sales forecast to about $101.2 billion at the midpoint, from $101.1 billion. Its adjusted earnings midpoint rose to $11.10 per share from $11.04. Shares closed at $263.73 on Monday, up 27% this year.